Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

WHO approves world's first malaria vaccine
Malaria is a leading cause of childhood illness and death in sub-Saharan Africa.
Pilot study led to a 30 per cent reduction in severe malaria in parts of Africa.

The World Health Organization (WHO) has recommended the use of a malaria vaccine among children in countries with moderate to high transmission of the disease.

The recommendation of the RTS, S malaria vaccine is the result of an ongoing pilot study taking place in Ghana, Kenya and Malawi, which has reached more than 800,000 children since 2019.

WHO director-general Dr Tedros Adhanom Ghebreyesus dubbed the long-awaited vaccine as a “historic moment” and that it “could save thousands of young lives each year”.

Spread by the P.falciparum parasite, malaria is a leading cause of childhood illness and death in sub-Saharan Africa; every year the disease kills more than 260,000 children in the region aged under five. 

In recent years, however, the WHO and partners have been reporting a stagnation in progress against the disease.

Dr Matshidiso Moeti, WHO regional director for Africa, commented: "For centuries, malaria has stalked sub-Saharan Africa, causing immense personal suffering. We have long hoped for an effective malaria vaccine, and now for the first time ever, we have such a vaccine recommended for widespread use.”

To date, more than 2.3 million doses of the RTS, S vaccine, developed by GSK, have already been administered as part of the pilot study. Key findings show that the vaccine is feasible to deliver, safe and cost-effective, even in areas with high malaria transmission. 

In the countries where the vaccine was administered, there was a 30 per cent fall in deadly severe malaria, even where malaria nets are used and there is good access to diagnosis and treatment. 

Dr Tedros said: “This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control. Using this vaccine on top of existing tools to prevent malaria could save tens of thousands of young lives each year.” 

Later this year, Gavi, the Vaccine Alliance is expected to consider financing a broader vaccine rollout across Africa. The WHO will also work with regional health organisations about whether to adopt the vaccine as part of national malaria control strategies.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.